Comparison of Abacavir Following Once-Daily And Twice-Daily Administration In HIV Infected Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2005-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to look at the levels of the drug abacavir (ABC) in blood. Also, the study will look at the levels of carbovir triphosphate (CBV-TP), which is the active substance produced from ABC in the bodyâ s cells which helps prevent HIV from multiplying. CBV-TP will be measured in specific blood cells. The amount of ABC and CBV-TP will be looked at when subjects receive ABC as a 300mg dose twice a day and compared with the levels when they receive ABC as a 600mg dose once a day.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Abacavir Pharmacokinetic Study in the Absence/Presence of Darunavir/Ritonavir or Raltegravir in HIV-infected Subjects

NCT00765271

HIV

COMPLETED PHASE1

A Study of 1592U89 in HIV-Infected Patients

NCT00002388

HIV Infections

COMPLETED PHASE1

An Open-Label Study to Evaluate the Efficacy and Safety of Amprenavir (141W94) and Abacavir Combination Therapy in Protease Inhibitor Experienced Subjects With HIV-1 Infection Who Are Failing Their Current Antiretroviral Treatment Regimen

NCT00002205

HIV Infections

COMPLETED NA

A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment

NCT00004581

HIV Infections

COMPLETED PHASE3

Effectiveness of the Early Addition of Abacavir to an Anti-HIV Drug Combination

NCT00001132

HIV Infections

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

abacavir

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy adults , inclusively.
* Documented HIV-1 infection (documented by historical data or current validated assay).
* Undetectable viral load.
* Currently on an ABC-tablet containing regimen for at least 8 weeks.
* Willingness to temporarily switch ABC schedule from BID to QD, or vice versa, for 11 days.
* Weigh between 40-100kg, inclusive.

Exclusion Criteria

* Subjects who are receiving tenofovir.
* Previous study participation in other experimental drug trial(s) within 30 days before the screening phase of the study.
* Subjects who currently regularly take drugs-of-abuse, with the exception of cannabinoids.
* Subjects who cannot refrain from taking herbal remedies during the course of the study.
* Subjects who regularly consume more than an average amount of alcohol per day.
* Poor general health preventing fasting or blood sampling.
* Subjects who are not able to discontinue use of hydroxyurea, mycophenolate or ribavirin for 14 days prior to entering the study until discharge from the study.
* An unwillingness of a male subject to abstain from sexual intercourse with women of childbearing potential or an unwillingness to use a condom in addition to having their female partner use another form of contraception.
* The subject is pregnant or nursing an infant.
* History of symptoms consistent with a hypersensitivity reaction to ABC.
* Positive HCV Antibody or HepBsAg (Hepatitis B surface antigen).

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes